EORTC MELANOMA GROUP MEETING

Transcription

1 The future of cancer therapy EORTC MELANOMA GROUP MEETING OCTOBER 27 th AND 28 th Olissipo Oriente Hotel LISBON PROGRAM OFFICIAL AGENCY

2 EORTC MELANOMA GROUP MEETING Dear Colleagues, The EORTC Melanoma Group meeting is going to be held in Lisbon, Portugal, in October, 27 th and 28 th Portugal, with almost 900 years of history is the oldest nation-state in Europe and Lisbon, its capital is the city located further west in Europe and it is located on the north bank of the Tagus river estuary, which flows into the Atlantic Ocean. Both river and sea proximity, offers to Lisbon a very special mild climate and a unique light. The seven hills city is also known for the excellent cuisine, for its ancient and picturesque corners that contrasts between modern and cosmopolitan area. Lisbon in the fifteenth and sixteenth centuries has become known by the Portuguese Discoveries, through its maritime port from where the caravels left and arrived to Africa, Asia, Oceania and South America, expanding Western influence by all continents and establishing an empire that lasted nearly 600 years. I have a huge pleasure to welcome you to Lisbon as I m member of this group from more than 20 years and hope this meeting reaches all the scientific goals and also that you enjoy the time spent with us. Yours sincerely, Maria José Passos Local Chairman

3 OCTOBER th Thursday ROOM PEQUIM B 11:00-16:00 Young Investigators Meeting 11:00-11:20 SDHD promoter mutations and SDHD protein expression in cutaneous melanoma Helena Pópulo, IPATIMUP, Portugal 11:20-11:40 Deciphering the Roles of the PP2A Phosphatase Subunit PR70 in Melanoma. Andreas Papadakis, McGill University, Canada 11:40-12:00 ckit mutation or amplification predicts high sensitivity to dasatinib in melanoma while MITF-BCL2 activation is associated with resistance to the drug Fabrice Journe, Institut Jules Bordet, Belgium 12:00-12:20 Adjuvant dendritic cell vaccination in stage III melanoma patients induces tumorspecific T cell responses and shows favorable overall survival Kalijn Bol, Radboudumc, The Netherlands 12:20-12:40 Development of CD4+ T-cell resistance in the course of melanoma progression culminates in total T-cell resistance in the context of MHC class I deficiency Christina Heeke, University Hospital Essen, Germany 12:40-13:00 A monocyte-nk cell partnership established by the primary tumour strongly inhibits melanoma metastization to the lung Hiroshi Kubo, Faculdade de Medicina, Portugal 13:00-14:00 Lunch 14:00-14:20 Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients Max Madu, Netherlands Cancer Institute, The Netherlands 14:20-14:40 Randomized phase III study comparing non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of TIL and IL-2 to standard ipilimumab treatment in metastatic melanoma M.H. Geukes Foppen, Netherlands Cancer Institute, The Netherlands 14:40-15:00 Cytomegalovirus reactivation in patients with ipilimumab-induced colitis Cindy Franklin, University Hospital Essen, Germany 15:00-15:20 Favourable prognostic role of Histological regression in stage III Melanoma patients Simone Ribero, University of Turin, Italy 15:20-15:40 Global discussion

4 OCTOBER th Thursday ROOM MACAU A Pathology Course Daniela Massi, Joaninha Costa Rosa (local pathologist) Course Moderators: Martin Cook, UK Martin C. Mihm. Jr., USA Speakers: Martin Cook, Guildford, UK Senada Koljenovic, Rotterdam, The Netherlands Martin C. Mihm, Boston, USA Joost van den Oord, Leuven, Belgium Case 1 Martin C. Mihm, Boston, USA Case 2 Martin C. Mihm, Boston, USA Case 3 Martin C. Mihm, Boston, USA Case 4 Joost van den Oord, Leuven, Belgium Case 5 Joost van den Oord, Leuven, Belgium Case 6 Senada Koljenovic, Rotterdam, The Netherlands Case 7 Senada Koljenovic, Rotterdam, The Netherlands Case 8 Martin Cook, Guildford, UK Case 9 Martin Cook, Guildford, UK Case 10 Martin Cook, Guildford, UK Discussion and closing remarks

5 OCTOBER th Thursday ROOM PEQUIM B 18:00-19:00 Keynote lecture New frontiers in immune-oncology of melanoma Prof. Bruno Silva Santos Instituto de Medicina Molecular, Lisboa 19:00 Discussion Group Dinner 19:30 Transfer from Hotel 20:00 Dinner at Café Inn Restaurant

6 OCTOBER th Friday ROOM PEQUIM B 08:00-08:45 Registration 08:45-09:00 Welcome by local organizer (Maria José Passos) and MG Chair (Caroline Robert) 09:00-10:20 Plenary session 1 Topics : Surgery, Pathology, Early Stage & Epidemiology 09:00-09:20 The role of the pathologists in the diagnosis and treatment of malignant melanoma Alistair Robson, Portuguese Institute of Oncology, Lisbon, Portugal 09:20-09:40 Sun exposure, skin protection and public health campaigns: a Portuguese perspective João Maia Silva, CUF Descobertas Hospital, Lisbon, Portugal 09:40-10:00 Electrochemotherapy for locally advanced Melanoma Victor Farricha, Instituto Português de Oncologia, Lisbon, Portugal :20 In situ evaluation of markers of activation and inhibition of Tumor Infiltrating Lymphocytes (TILs) after microdissection: remarks to the current morphologic classification of the TILs patterns. Francesca Maria Bosisio 10:20-11:00 Coffee Break 11:00-12:00 Plenary session 2 Topics : Ocular, Systemic (Stage IV and Adjuvant), TR 11:00-11:20 MC1R variants predict melanoma development independently of at risk phenotypic characteristic Sara Raimondi, IEO, Italy 11:20-11:40 Developing advanced immunocompetent 3D human skin melanoma models Barbara Assimonti, University Piemonte Orientale, Italy Stefania Pizzimenti, University of Turin, Italy 11:40-12:00 Phase 2 study comparing pembrolizumab with intermittent/short-term dual MAPK pathway inhibition plus pembrolizumab in patients harboring the BRAFV600 mutation (IMPemBra Trial) Lisette Rozeman, Netherlands Cancer Institute, The Netherlands 12:00-13:00 Lunch

7 OCTOBER th Friday ROOM PEQUIM B 13:00-15:30 Plenary session 3 Study Proposals 13:00-13:30 MSOT Validation Study 13:30-15:30 Break-out sessions Epidemiology, Early Stage, Surgery, Pathology, Ocular, Systemic (Stage IV and Adjuvant) 15:30-16:00 Coffee Break 16:00-17:30 HQ trial reports 17:30-18:30 Sub-Committee Reports & Decision Making / Voting on New Proposals 18:30 Meeting Closure MALACA ROOM 19:30-22:30 Steering Committee Meeting

8 The future of cancer therapy OFFICIAL AGENCY